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Introduction
A biosensor may be considered a three component system comprising: (a) the sample or analyte, (b) a transducer mechanism or bioreceptor and (c) a signal output. This report focuses on how altering the bioreceptor may be a crucial step in overcoming the barriers in the production of sensitive, low cost biosensors for both diagnostic and analytical applications. Though many sensors have been developed at the proof -of -concept level, there are only a few examples which have made the leap into the commercial market [1, 2] .
Most of the binding sensors developed to date rely on antibodies, the primary recognition agent of the immune system [3] and will be referred to as immunosensors throughout. Though antibodies are common reagents with well understood binding physics which allow the use of routine methods, there are a number of major drawbacks. These include batch to batch variability when using polyclonal antibodies, stability of the antibodies and their large size (150kDa) which precludes the possibility of protein engineering. Antibodies may also bring issues of cross reactivity which cannot be identified until after production. These technical shortcomings are in addition to the ethical issues raised by their reliance on animal use and the financial issues raised with their associated cost [4, 5] .
For these reasons, there is a movement towards the use of recombinant monoclonal antibodies and the use of non-antibody binding proteins (NABPs), the latter of which may be easily expressed using bacterial techniques which allow the continuous production of a stable protein with no variation.
Whilst this article focuses on the use of nanobodies, the lessons learned may support findings relevant to other types of NABP or engineered Fab fragments or single chain variable fragments (ScFvs). There are currently a number of candidate NABPs for biosensor development such as darpins [6] Adhirons [7] and affybodies [8] . Though the benefits of these receptors have been previously demonstrated using optical biosensor systems [9] , there are limited reports on their application in electrochemical sensors and specifically a lack of data reported for impedimetric immunosensors [10] . There is no work to date focussing on both the orientation and inclusion of a peptide spacer to investigate the influence of bioreceptor height above the electrode on detection of analyte and signal generation.
The nanobody binding protein used in this study is an IgG fold domain which has been isolated from cammellid heavy chain only "Immunoglobulin New Antigen Receptors" (IgNARs). cDNA from lymphocytes was taken from immunised Cammellidae [11] [12] [13] . The cDNA can be sourced from lymphocytes isolated from blood taken from the host, avoiding animal sacrifice and contributing to the 3R's of animal use in research.
The cDNA extracted was isolated using PCR and used to construct a phage display library that could be screened to identify binding candidates for nanobody synthesis before sequencing and subcloning the DNA into a stable plasmid vector [14] . Screening can also be carried out at this stage to check for cross reactivity with candidate biomolecules which may commonly cross react with receptors [15] . This enables the elimination of receptors which cross react before the receptor is generated en-masse.
Once the DNA is ligated into a plasmid, it contains the sequence for a monoclonal-type binder and batch to batch variability is eliminated. This means that only one immunisation is necessary for a potentially endless source of nanobodies, producing a binder that is more reliable when compared to polyclonal antibody production techniques, as well providing the potential for lower cost [16] . These benefits have enabled the development of novel [17] [18] [19] [20] , as well as showing early promise in the field of diagnostics [20, 21] .
The nanobody used in this report was engineered to include a His6-Tag for easy purification. In addition the plasmid was further engineered to create nanobodies with an engineered peptide spacer of 5, 10 or 15 amino acids (a GGGGS motif repeated respectively) with a unique cysteine at the N-terminus to enable oriented conjugation of the receptor using thiol chemistry, the plasmids are summarised in Appendix A. Along with orientation, the use of spacers permitted the optimisation of receptor distance from the transducer surface, a parameter which may greatly impact the electrochemical signal generated.
Whilst the majority of reports aim to attach the bioreceptor intimately at biosensor interface, this may cause undesired effects such as a limitation in analyte binding due to steric hindrance. By providing a spatially coherent peptide spacer, these problems may be overcome as well as an improved degree of receptor orientation. The effect of steric hindrance has been demonstrated as a critical parameter in biosensor signal generation in previous studies [22] [23] [24] [25] . It is hypothesised that the use of nanobodies will highlight the importance of orientation of the bioreceptor. As a comparison to the novel nanobody biosensors, data has been collected on antibody based biosensors; the variety of bioreceptors used in this study is illustrated in Figure 1 .
The sensor constructed in the study was developed to specifically detect rabbit IgG, for the commercial demands of the antibody development industry. The sensor developed will provide an accessible method for assaying antibody concentration in both sera and in prepared antibody products. Currently, a multi-step procedure is needed to quantify rabbit IgG accurately, this is inefficient in terms of both time and resources as it often relies on relatively large sample volumes.
Materials & Methods

Expression and Purification of nanobodies.
A series of pHEN6 vectors was generated to create anti-rabbit IgG nanobodies, based on ab191866 (Abcam), the sequence was cloned into each modified pHEN6 vector using PstI and BstEII sites (Error! Reference source not found.) and modified vectors were generated by ligating in the sequence for include C-terminal spacers with a G4S motif (repeated for 5, 10 and 15 amino acid spacers with a terminal cysteine (Error! Reference source not found.) followed by a His6-tag. This was achieved using BstEII and EcoRII sites. Following ligation, plasmids were transformed into WK6 E.Coli cultures using the heat shock method [26] and cultures were grown on Ampicillin containing TB -Agar plates pre-heated to 37 °C. Individual col onies were then picked and added to 5 ml LBampicillin media to form starter cultures. The following day, 2 ml of this culture as added to 500 ml LB -ampicillin and IPTG was used to induce cultures overnight.
Cells were collected by centrifugation at 3,000 xg for 30 min. The periplasm was then extracted using TES buffer (0.2M Tris-HCL 0.5M Sucrose 0.5mM EDTA) at 4 °C, shaking on ice for 1 hr. Finally, cell deb ris were collected by centrifugation at 6,800 xg for 5 min. The Periplasm extract was then purified on a Ni 2+ chelating column as previously described [27] and imidazole was removed by dialysing the nanobody against PBS.
Reduction of nanobody dimers
The purified nanobody at 1 mg.ml -1 was incubated with 50 mM 2-mercaptoethylamine (2-MEA), in degassed PBS plus 10 mM EDTA pH 7.4 for 90 min at 37 C T bonds, reducing Nanobody dimers into monomers. Buffer exchange was then executed using Amicon® filters (3,000 MWCO) which were centrifuged at 14,000xg for 10 min to remove excess MEA. Buffer was replaced three times with previously degassed 1×PBS plus 10mM EDTA pH 7.4. Reduced nanobodies were then used immediately to prevent recombination of reduced nanobodies.
Immunoprecipitation
For immunoprecipitation studies, unmodified nanobodies were conjugated to N-Hydroxy succinimide (NHS) (GE Healthcare) and the modified nanobodies were conjugated to Sulfolink®(Sigma) sepharose beads according to manufacturers' protocols. Non-specific binding was reduced by blocking beads with glycine in the case of NHS beads and cysteine for Sulfolink beads (50mM cysteine in 50mM Tris-Hydroxymethylaminomethane plus 5Mm EDTA).
To confirm the affinity of the nanobodies had not been compromised, the beads were incubated PBS A performed using 100 mM sodium citrate (pH 4.0) and a final RIPA Buffer wash (50mM NaCl, 1% (v/ v) IGEPAL CA-630®, 0.5% (w/ v) sodium deoxycholate, 0.1% (w/ v) SDS and 50 mM Tris, pH 8.0) to remove non-specifically bound protein from the beads.
For elution, a two stage procedure was employed. First, 100 mM glycine (pH 2.0) elution buffer was used to interrupt nanobody-antigen binding and elute bound analyte. Then, a second elution buffer containing PBS + 100 mM DTT was used to liberate the modified nanobody from the Sulfolink® bead. This provided confirmation that the nanobody had bound via the engineered cysteine residue.
Identification of eluates
For identification, eluates from immunoprecipitation were subjected to non-reducing SDS-PAGE.
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(v/ v) glycerol, 0.01% (w/ v) bromophenol blue (w/v)] were heated for 10 min at 70 C to pre-cast gels (4-12% acrylamide) (Invitrogen). Gels were run at 200 V for 50 min in 1x Trid-glycine running buffer. Following separation, the gels were either stained using Instant Blue® Coomassie stain, according to manufacturer's instruction or used for immunoblotting.
In immunoblot experiments, samples were transferred to nitrocellulose membrane at 30 V for 70 min in transfer buffer and transfer was confirmed using Ponceau-stain which was subsequently washed using TBST (20 mM Tris, 150 mM NaCl 0.1 % (v/ v) Tween-20 pH 7.6). Membranes were then blocked using 5% (w/ v) BSA in TBST before being probed with the appropriate HRP-antibody conjugates at 1:10,000 dilution in blocking buffer. Membranes were then washed thoroughly before adding ECL Substrate (SuperSignal®, Pierce) and imaging using a Syngene® G:Box System.
Biosensor construction and Bioreceptor Conjugation
Electrode Preparation
Customised DropSens® X2220AT gold electrodes were cleaned by ultra-sonication in 100 % ethanol for 10 min before rinsing in dH2O and drying in a stream of argon. The working electrodes were then coated in a matrix of polytyramine by electropolymerising from a monomer solution (25 mM tyramine in 300 mM NaOH in MeOH) in accordance with previously established methods [28, 29] . The solution was electrochemically polymerised onto the electrodes using cyclic voltammetry, with potential cycled between 0 V and 1.6 V (vs. Ag/AgCl) with a scan rate of 0.2 V.s -1 for two consecutive scans data shown in (Appendix C), before equilibrating for 15 min in PBS pH 7.4.
Oriented conjugation of spacer modified nanobodies
The polymer modified electrodes were incubated with 5 mM sulfosuccinimidyl 4-[Nmaleimidomethyl] cyclohexane-1-carboxylate (Sulfo-SMCC, Sigma) solution in 10 mM PBS-EDTA (10mM) pH 7.2 for one hour, as described in previous papers [30] .Freshly reduced nanobodies (from 2.2) were then added to the sulfo-SMCC modified electrode and incubated for 1 hr. These electrodes were incubated for 30 min in PBS pH 7.4 to remove any non-specifically bound receptor. The sensors were interrogated electrochemically prior to analyte detection to obtain a baseline sensor signal.
Non-Oriented Conjugation of full antibodies and nanobodies
For non-oriented bioreceptor studies, the bioreceptor (either Goat anti -rabbit IgG, ab 97047 (Abcam) or the nanobody) was firstly biotinylated using biotin-XX-NHS (Merck Millipore) according to established protocols [31] . Biotinylated bioreceptors were then stored at -20 C After electrode preparation (2.5.1), 3 mM biotin-NHS PBS DMSO was added to the working electrode for 60 min. After copious washing, 1mM Neutravidin® was added to the incubated for 1 h. The electrodes were once again incubated for 30 min in PBS after sensor assembly and a baseline signal obtained.
Biosensor Interrogation
After sensor assembly, electrochemical impedance spectroscopy (EIS) was used to monitor analyte recognition. Data was processed using NOVA software on a FRA-2 µAUTOLAB type III electrochemical workstation. The impedance analysis was performed over a frequency range from 0.25 Hz to 25 kHz, using a modulation voltage of ±10 mV at an applied voltage of 0.0V with respect to the reference electrode. All impedance experiments were performed in an electrolyte solution of 10 mM K3[Fe(CN)6]/ K4[Fe(CN)6] (1:1 ratio) in 1xPBS, pH 7.4. Fully fabricated immunosensors were -9, ab26414 (Abcam)) at a concentration ranging from 666 fM to 666 nM for 30 min prior to sensor interrogation. The EIS response was read following copious rinsing of the analyte.
Data Analysis
Using Autolab NOVA Software, impedance data was modelled using a modified Randles' circuit in which the pure capacitor was replaced with a constant-phase element to simulate the non-ideal nature of capacitance at the biosensor surface [32] (see Figure 4 (B) inset) . As the effects of Warburg impedance were not observed in the data, this component was also excluded from the model. Using this analysis, the simulated fit was found to have a deviation of 2.89 %± 0.096 (n=64) from the measured data.
This fit generated values for Solution resistance (Rs), Charge Transfer resistance (Rct) and constantphase element (Q). For calibration of the biosensor Rct was used as it was the most sensitive to analyte binding and is the most widely used measure for impedimetric analysis of biosensors in the field [32] [33] [34] [35] [36] . To ensure chip-to-chip variability was minimised, values were normalised to the initial baseline of the RCT measured for the fully constructed sensor.
Results
Optimisation of synthesis and Dimer Reduction
Nanobodies were successfully expressed in E.coli before being purified. In nanobodies with engineered cysteine terminal receptors, dimers natively formed. These dimers were reduced by incubation with 2-MEA (90mM, 37 C C is illustrated in Figure 2 . All lanes were run under non reducing conditions to ensure successful reduction of dimers could be observed. In all conditions the increasing molecular weight of the nanobodies can be observed, owing to the successful inclusion of the lengthening peptide spacer. The overall sample purity can also be clearly seen.
Immunoprecipitation of IgG from rabbit sera
Immunoprecipitation experiments illustrated that reduction had not denatured the nanobodies and that the use of the spacer had not interfered with the immune recognition of IgG by the nanobodies (Figure 3) . In this figure the Coomassie of different elutions from the experiment is shown with corresponding blots for the analyte as well as the nanobody receptors. Figure 3(A) was done to assess the protein present in sera flow-through (s), glycine elution (gl) and DTT elution (dtt) of the immunoprecipitation experiments. Upon elution using glycine buffer bands can be observed at ~150 KDa corresponding to the molecular weight of IgG. When eluting with DTT bands are observed in the 12-15 KDa region, these correspond to the increasing molecular weight of the nanobody with their respective amino acid spacer.
Coomassie staining
The identity of these bands was confirmed in western blot; firstly using a goat-anti-rabbit -HRP conjugated antibody (Dako cat# P0448) to identify the IgG band (Figure 3(B) ). Secondly; an antiHis6Tag -HRP conjugated antibody (Abcam cat# ab1187) was used to identify the nanobody, a band at 12-15KDa (Figure 3(C) ). Across lanes, the signal is observed at increasing molecular weights corresponding to the 5, 10 and 15 amino acid peptide spacer modified nanobodies.
Biosensor Construction and Interrogation
Cyclic voltammetry (CV) verified the cleanliness and reproducibility of the gold surface before sensor construction (data not shown). Tyramine was then electrochemically polymerized on to the gold electrode in order to obtain a robust polymer with primary amino groups to permit functionalization of the sensor surface [29, 37, 38] . A characteristic cyclic voltammogram was seen across the two voltammetric cycles (Error! Reference source not found.), confirming the success of electropolymerisation.
After the polymer was equilibrated in PBS for 15 min, biosensors were constructed as described before interrogation. Impedance measurements were taken from 25 KHz-250 mHz and Nyquist plots were constructed. Nyquist data as in (Figure 4 ) was used to assess the binding. The difference between specific (Figure 4(A) ) and non-specific signal (Figure 4(B) ) can be seen in the nyquist data.
In order to allow cross comparison of the different nanobody biosensors with variable spacers against conventional antibody methods, Rct was analysed by modelling the equivalent circuit displayed in Figure 5 , inset. The Rct was then used to calculate the average percent change compared with the initial sensor reading and construct a calibration. As sensors were interrogated suing specific rabbit IgG analyte and negative sheep IgG, a comparison of analyte specific signal obtained from different bioreceptor systems can be seen in Figure 5 .
It can be seen from this data that when using IgG as a receptor, the addition of analyte causes an increase in the resistance across the sensor interface. This follows conventional findings in the development of impedimetric immunosensors [3, 35, 39, 40] , as the passing of ions across the interface is slowed upon anlyte binding, corresponding to an increase in effective resistance.
However, when using biotinylated nanobody as the receptor this is not the case. Instead a decrease in the resistnace is observed. To confirm this, controls were performed with negative and positive controls using another sensor (for GFP constructed using anti-GFP nanobodies, (ab192863,Abcam) (Error! Reference source not found.). This confirmed that the decrease in resitance is both analyte dependent and observed consistently when using biotinylatyed nanobodies directly. This problem was successfully circumvented when using the oriented spacer.
From data in Figure 5 we can observe that the use of an oriented peptide spacer of five amino acids was the optimum as it generated a large signal and was more sensitive, still generating appreciable signal at the lowest concentration of anlyte (666 fM). Biosensors constructed using ten amino acid spacers generated signal which was comparable to that obtained when using IgG as a receptor. When using a receptor with a fifteen amino acid spacer however there was negligible generation of specific signal.
Optimisation of best candidate
As the biosensor constructed using a bioreceptor with five amino acid peptide spacer had been identified as the best candidate, this was taken forward to be interrogated using a full panel of controls ( Figure 6 ) in relevant sampling media to mimic sera. The sensor was interrogated with in PBS as an ideal system as well as a negative control using sheep IgG, data for these experiments was used to obtain calibration from Figure 5 . In addition to this, human sera at both 100 and 10 % v/ v in PBS was spiked with the same rabbit IgG to ensure that the biosensor is operational in a relevant sampling matrix.
This demonstrated the successful detection of analyte in full sera and the overall specificity of the sensor in a complex media. Given that sera has a reference value of 60-80 mg.ml, an extremely high concertation when comparing to reference analyse range of the developed sensors , the sensor has proven successful. When using undiluted sera an inferior calibration was observed. This may be due to the very high concentrations of non-specific proteins in the sample suppressing generation of signal by the analyte. In this dataset, the highest concentration of analyte resulted in a sudden decrease of signal. This may be due to transducer or receptor disintegration given the repeated barrage of high concentration protein samples and the high number of incubation-interrogation cycles. The sample spiked in 10% sera is the most successful showing large signal generation. This represents a practical sampling method, where a commercial or medical sample would be diluted before application to the sensor.
Conclusion
In this study, an impedimetric immunosensor to rabbit IgG was fabricated using bespoke nanobody constructs as bioreceptors and compared to traditional antibody based biosensors.
When using conventional biosensor construction techniques with nanobodies, a negative calibration emerged, i.e. impedance fell on analyte binding which runs counter to most findings in this area. This trend was confirmed using a variety of controls and in the development of a similar sensor for green fluorescent protein (GFP). In both instances a change of ~40% in the Rct was observed.
A peptide spacer was engineered to resolve this issue which also brought the advantage of orienting the receptor on the biosensor surface. The inclusion of the peptide spacer rectified the impedance drop and allowed the effect of spacing to be investigated. Optimisation of spacer length altered the signal and sensitivity of the sensor, leading to an improvement and a change of ~60% in the Rct to be observed. The optimal nanobody construct was observed with a peptide spacer of five amino acids. This sensor displayed reliable analyte specific signal down to pM analyte concentrations, demonstrating comparable sensitivity to established methods such as ELISA and superior performance to similar electrochemical biosensors [41, 42] . As typical samples have M concentrations, this biosensor has an appropriate functional range and allows for sample dilution which is beneficial for practical deployment.
In this study the spacer chosen had lengths of approximately 2, 4 and 6 nm which were compared to the solute layers present at the electrode interface. According to double layer theory and the GuoyChapman model [32] , the typical length of the Debye layer at the electrode interface of this electrolyte system has a thickness of ~3 nm [32, 43] . Using the five amino acid spacer therefore locates the receptor in the middle of the Debye layer. This may explain why the five amino acid spacer is optimal as longer spacers may place the receptor beyond the Debye layer, reducing the impedance signal generated upon analyte binding. The continued detection of analyte may be due to the spacer flexibility meaning that though the spacer length is greater than that of the Debye layer, it may flex and lead to some binding happening within the Debye layer. Along with the receptor being located optimally in the z-plane, the use of a five amino acid peptide spacer may also negate the effects of steric hindrance which could limit binding at the sensor interface. Though electrode surfaces are commonly depicted as planar surfaces, screen printed electrodes used are far from flat at the nanoscale. This irregular texture may prevent the analyte from binding to the receptor when is confined at the surface. The effect of steric hindrance has been previously identified as an issue in biosensor fabrication [23, 30, 44] .
Whilst this study is far from field deployment, improvements such as the reduction of chip-to-chip variability in the electrodes and automated sensor construction techniques could create more reliable sensors and enable effective point-of use testing comparable to ELISA assays or similar in a more user-friendly format. Using the recognised system of 'technology readiness levels' [45] , this work is currently at level 4-5, relatively nascent compared to the ELISA, a routine technique used in industry (level 9). This study has demonstrated for the fabrication of a sensitive and specific reagentless immunosensor using novel nanobody constructs. In addition to the advantages of using both unmodified and engineered nanobodies over polyclonal antibodies, this study presents insight relevant to the use of small binding proteins in electrochemical sensors, it is hoped that the lessons learnt in this study may inform the investigation of other NABP based sensors.
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